Key result
A new 35-mm endovascular size reducer was successfully deployed in 6 sheep with no prosthetic migration and low transprosthetic systolic gradient (4+/-2.5 mm Hg) after 8-12 weeks.
Why the study?
Does a new endovascular size reducer enable successful percutaneous pulmonary valve implantation in a large pulmonary outflow tract model?
Population
n=6 sheep
Design
Preclinical
Follow-up
8-12 weeks
Authors
Loading...
May support percutaneous pulmonary valve implantation in large outflow tracts; leaves open human translation.
Does a new endovascular size reducer enable successful percutaneous pulmonary valve implantation in a large pulmonary outflow tract model?
A novel endovascular size reducer demonstrates feasibility and effectiveness in a sheep model, potentially extending percutaneous pulmonary valve implantation to patients with large outflow tracts.
Amahzoune et al. (2009) studied Large ventricular outflow tract requiring percutaneous pulmonary valve implantation (n=6). 35-mm endovascular size reducer was evaluated on Device positioning, residual stenosis, and prosthetic migration. A new 35-mm endovascular size reducer was successfully deployed in 6 sheep with no prosthetic migration and low transprosthetic systolic gradient (4+/-2.5 mm Hg) after 8-12 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: